Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN5A | Q14524 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TOP2A | P11388 | 1/20 | 0.30 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20549485 | 0.79 | SCN5A (0.41) | SCN5AKCNH2KDM4ESMN1; SMN2CYP1A2 | |
| SCHEMBL20549502 | 0.78 | HIF1A (0.36) | KDM4ELMNA | |
| SCHEMBL20549418 | 0.77 | KCNH2 (0.48) | SCN5AKCNH2KDM4ESMN1; SMN2CYP1A2 | |
| SCHEMBL20549899 | 0.77 | TOP2A (0.43) | SCN5AKCNH2KDM4ESMN1; SMN2CYP1A2 | |
| Hydrochloric Acid SCHEMBL20549561 | 0.74 | SCN5A (0.67) | SCN5AKCNH2KDM4ELMNA | |
| Hydrochloric Acid SCHEMBL20552385 | 0.74 | SCN5A (0.67) | SCN5AKCNH2KDM4ELMNA | |
| SCHEMBL17494296 | 0.73 | SCN5A (0.57) | SCN5AKCNH2TOP2ATOP2B | |
| SCHEMBL20549202 | 0.70 | KCNH2 (0.50) | SCN5AKCNH2KDM4ESMN1; SMN2CYP1A2 | |
| SCHEMBL20549518 | 0.68 | ALDH1A1 (0.33) | SCN5AKCNH2KDM4ELMNA | |
| SCHEMBL20549817 | 0.67 | ALDH1A1 (0.34) | SCN5AKCNH2KDM4ESMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180318311-A1 | TRICYCLIC 2-QUINOLINONES AS ANTIBACTERIALS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2018-11-08 | — | — | US | disclosed |
| WO-2018203302-A1 | TRICYCLIC 2-QUINOLINONES AS ANTIBACTERIALS | NOVARTIS AG (CH) | 2018-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180318311-A1 | TRICYCLIC 2-QUINOLINONES AS ANTIBACTERIALS | TOP1, TOP2A, TOP2B | SCN5A 1467/4885KCNH2 2920/4885KDM4E 2521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.